Navigation Links
ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
Date:4/14/2008

- Conference Call to Discuss Results to Be Held at 9:00 A.M. -

EXTON, Pa., April 14 /PRNewswire-FirstCall/ -- ViroPharma Incorporated's (Nasdaq: VPHM) first quarter financial results for 2008 are expected to be released on Wednesday, April 30, 2008 before the open of the U.S. financial markets.

The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day. During the conference call, ViroPharma management will discuss the 2008 first quarter financial results and other business.

The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com. An audio archive will be available at the same address until May 14, 2008. To participate in the conference call, please dial (877) 366-0713 (domestic) and (302) 607-2000 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin- resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its d
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma to Present at Three Upcoming Healthcare Conferences
4. New Research for Mechanical Support Devices in Pediatrics to Be Released at International Heart and Lung Transplant Meeting
5. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
6. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
7. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
8. DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With the Release of 5.0
9. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
10. Keppra XR(TM) Extended-Release Tablets Filed with the FDA
11. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2008)...olled in Clinical Trial to Assess Survival of Pati...ies for Unresectable Hepatocellular Carcinoma , ...ght Sciences Oncology, Inc. (LSO) today announced ...linical trial of Light Infusion Therapy(TM) (Litx(...r carcinoma (HCC), also known as hepatoma or prima...
(Date:11/24/2008)..., Nov. 24 Domino,s Pizza (NYSE: ...ery, is gearing up to raise dough for,the kids of...fifth annual,Thanks and Giving campaign. Domino,s...nation at point of purchase to benefit the childre...g over the phone or when ordering online at, www....
(Date:11/24/2008)...s its innovation leadership and long-term commitme...J., Nov. 24 Schering-Plo...inical update on boceprevir, its lead investigatio...in Phase III development. The company believes bo...and best-in-class protease inhibitor for treating ...
(Date:11/24/2008)... /PRNewswire-FirstCall/ - Predictive medicine comp...d that it has entered into a fully funded collabor...st cosmetic companies. PreMD,s PREVU* skin cholest...the cosmetic company,s skin care products in a Eur...essful study completed by PreMD with the cosmetic ...
Breaking Medicine Technology:Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 2Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate 2Use of information technology is minimal in nursing homes 16245 1Use of information technology is minimal in nursing homes 16245 2Ancient DNA 3A reconstruction of the biological history of Aldaieta necropolis 2811 1Ancient DNA 3A reconstruction of the biological history of Aldaieta necropolis 2811 2Ancient DNA 3A reconstruction of the biological history of Aldaieta necropolis 2811 3Distance learning course in radiation oncology for cancer treatment 2809 1Distance learning course in radiation oncology for cancer treatment 2809 2American Society for Microbiology 108th General Meeting 2807 1American Society for Microbiology 108th General Meeting 2807 2
... CHAPEL HILL, N.C., US, March 06, 2007,/PRNewswire...and,Lantibio, Inc. ("Lantibio") today announced po..., double-blinded Phase II clinical,study of Moli19...sis ("CF"). Moli1901 is being developed by AOP Orp...ion agreement with,Lantibio. The study, performed ...
...SS WIRE)--Mar 7, 2007 - Accentia,Biopharmaceutical...,the Annual Meeting of the American Academy of All..., 2007 in San Diego, CA. The,posters discussed fin...) and allergists in the U.S., U.K., France, and Ge... knowledge and attitudes of,the fungal etiology of...
Other Medicine Technology:AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II,Study with Novel Cystic Fibrosis Therapy 2AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II,Study with Novel Cystic Fibrosis Therapy 3AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II,Study with Novel Cystic Fibrosis Therapy 4Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 2Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 3Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 4Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 5
(Date:12/2/2008)... Orion Health announces that the Sou...of Juneau, Alaska, has selected the Rhapsody&trade...nic health record, radiology, pharmacy, laboratory.... It also plans to extend connectivity to statewid...unization registry) and AKAIMS (an MIS and clinica...
(Date:12/2/2008)... Dec. 2 Population Serv...hensive project that could dramatically reduce the...malaria. The program will provide free artemisinin...community health workers to poor children suspecte...to treatment will be monitored to determine if it ...
(Date:12/1/2008)...es ,Asthma & Allergy Friendly, Toy Puppies to ... Much has been made of P...ily dog. But concerns about his daughter,s asthma...ew first-dad from making a decision. So, in the m...ica (AAFA) is donating 2 "asthma & allergy fri...
(Date:12/1/2008)...New research reveals that computed tomography (CT)...has the potential to screen for two diseases at on...h commonly affect adults over age 50. Results of t...ting of the Radiological Society of North America ...screening for colorectal cancer, we were able to i...
Breaking Medicine News(10 mins):Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 2Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 3Health News:Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saharan Africa 2Health News:Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saharan Africa 3Health News:Asthma and Allergy Foundation Helps New First-Dad Keep His First Promise 2Health News:CT colonography offers 1-stop screening for cancer and osteoporosis 2
...id could provide ample energy if used properly is ...rican Journal of Physiology - Endocrinology and Me...d colleagues Takeshi Hashimoto and Rajaa Hussien i...ratory add one of the last puzzle pieces to the la...
... to a report published in Geneva it was found that...research work on diseases such as AIDS and malaria... many developing countries, especially in sub-Saha...y the Global Forum for Health Research. Stephen Ma...
...cefully can sometimes be a problem especially when... facilities looms large. //Marilyn Rantz, nursing ... calls this as a slippery slope and says that ther...m getting onto this slope. Consumers say they nev...
...more number of bus drivers and conductors in India...is that of the bus conductor Ravindra Kamble (34).... conductors in the last one year have been tested ...programme was started by General Manager SS Kshatr...
Other Medicine News:Health News:Lactic acid a potent energy giver if used properly! 2
Inquiry H Steerable Catheter. Steerable atrial mapping catheter offers a variety of designs and a unique 45 offset for catheter stability. 10 to 24 electrodes, regular and large steerable curves, ina
The Explorer 360 and 360 Jr. catheters have a rotational connector for ease of use during procedures.
...or a complete line of deflectable coronary sinus (...all with the quality, reliability and precise perf...atheter technology. All of our deflectable coronar...gned and constructed to help minimize the frustrat...
Inquiry 5FR Soft HIS diagnostic catheters provide the electrophysiologist with a uniquely designed curve that allows for placement and recording in the HIS bundle. In addition, the soft tubing is des
Medicine Products: